source
- Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startupVersant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…
- Biopharma firms showcase non-amyloid Alzheimer’s strategies at CTAD 2026 conferenceBiopharma companies including Biogen, Bristol Myers Squibb and Roche gathered in Boston for the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, where they presented new data on their…